Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials-Reference-Cited by-同舟云学术

Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials

Published:2021-11-01 Issue:9 Volume:204 Page:1086-1096
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Imperial Marjorie Z.¹²^ORCID,Phillips Patrick P. J.²³^ORCID,Nahid Payam²³^ORCID,Savic Radojka M.¹²³^ORCID

Affiliation:

1. Department of Bioengineering and Therapeutic Sciences;

2. University of California, San Francisco, Center for Tuberculosis, and

3. Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference30 articles.

1. Advances in clinical trial design for development of new TB treatments: A call for innovation

2. Challenges in tuberculosis drug research and development

3. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

4. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

5. TRUNCATE-TB: an innovative trial design for drug-sensitive tuberculosis

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking the threshold: Developing multivariable models using computer-aided chest X-ray analysis for tuberculosis triage;International Journal of Infectious Diseases;2024-10

2. Percent of lung involved in disease on chest X-ray predicts unfavorable treatment outcome in pulmonary tuberculosis;2024-08-20

3. A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB;Journal of Antimicrobial Chemotherapy;2024-08-01

4. Association between HIV and acquisition of rifamycin resistance with first-line TB treatment: a systematic review and meta-analysis;BMC Infectious Diseases;2024-07-01

5. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis;The Lancet Global Health;2024-06